chrisvoncsefalvay/vaers-outcomes huggingface dataset:
04/11/2022 I woke up with a sore throat. I called the Hospital to get a PCR COVID test. Tested positive on 4/14/2022. On 4/15/2022 I received INV -MOLNUPIRAVIR 200mg. Stopped medication last night. I don't feel tired. I have a headache over my right eye, runny nose. I am not as exhausted as I was before. They gave me Benzonatate to take 3 times a day. I am not coughing as much any more. They sent me a diabetic tussin.
Developed an area of redness, 16 x 14 cm in size, 2 days after vaccines were given. Was seen and treated for this.
Duplicate vaccine was given to patient, and duplication was caught after administration. Patient says that he is not experiencing any side effects at this time and feels fine.
Patient was dx with COVID-19 on 1/14/2021. She received the vaccine on 1/12/2021.
Several small pruritic papules and tender lt arm axillary lad, noted following Boostrix given 8/12/06. Tylenol or Motrin for pain, Benadryl or Claritin for itch.
On September 11, 2022, in preparation for my booster shot I took a pregnancy test at home, and it was positive.  I got my flu shot and my COVID-19 booster the same day.  Two weeks later the doctor confirmed I was pregnant.  I had two appointments when we were able to hear the baby?s heartbeat at six weeks.  Two week later when I was 8 weeks pregnant there was not heartbeat.  We gave the doctor permission to send the fetus for testing and research.
On 3/22/00, the pt received her first adult IM dose of Havrix. Within seconds, post vax, she became severely pale and fainted. Her loss of consciousness lasted a few seconds and the episode resolved in 5-10 minutes. No treatment was given. As of 9/21/00, the outcome of the event was resolved.
Mo reported that pt was  irritable & crying high pitched for approx 36hrs; t100 AX;
Illness; Head ache; Body aches; This case was reported by a other health professional via call center representative and described the occurrence of feeling unwell in a female patient who received Rabies NVS (RabAvert) for prophylaxis.   On an unknown date, the patient received RabAvert. On an unknown date, unknown after receiving RabAvert, the patient experienced feeling unwell, headache and general body pain. On an unknown date, the outcome of the feeling unwell, headache and general body pain were unknown.   It was unknown if the reporter considered the feeling unwell, headache and general body pain to be related to RabAvert.  Additional details were provided as follows: It was unknown if exposure was pre or post exposure. The age at vaccination was not reported. The HCP stated that the patient had headaches, body aches and illness. The case had been linked with US2020206868 reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020206868:same reporter
has a rash on his left leg starting (6/23/21); had fatigue/ Tired; appetite loss; dose number two given 6/21/21, 8 months after first dose; This case was reported by a consumer via call center representative and described the occurrence of fatigue in a 70-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on an unknown date).   On 21st June 2021, the patient received the 2nd dose of Shingrix (intramuscular). On 21st June 2021, unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On 22nd June 2021, the patient experienced fatigue and appetite lost. On 23rd June 2021, the patient experienced rash. On an unknown date, the outcome of the fatigue and appetite lost were recovered/resolved and the outcome of the rash was not recovered/not resolved and the outcome of the drug dose administration interval too long was unknown.   It was unknown if the reporter considered the fatigue, appetite lost and rash to be related to Shingrix.  Additional details were provided as follows: The reporter was the patient. The reporter stated that, after vaccination with 2nd dose of Shingrix, had fatigue and appetite loss and rash on his left leg. 1 day after vaccination with Shingrix, the patient experienced fatigue, appetite lost. 2 days after vaccination, the patient experienced rash. The patient received 2nd dose 8 months after first dose, which led to lengthening of vaccination schedule. The reporter did not consent to follow up.
Onset of swollen, tender superclavicular node (L) then swelling of deltoid (L) @ site of inject;
Returned 3 days, post vax, with fever of 99.4, muscle aches, redness at injection site and itching. Most of arm is red.
a little sore arm; This is a spontaneous report from a contactable consumer (patient herself). This consumer reported for similar events. This is the first of the two reports.   A female patient of an unspecified age received the first dose bnt162b2 (BNT162B2 also reported as PFIZER-BIONTECH COVID-19 VACCINE, lot/batch number and expiry date were not reported), via an unspecified route of administration on 22Dec2020 at SINGLE DOSE for Covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced a little sore arm on an unspecified date. The outcome of event was unknown.  The information on the lot number has been requested.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021149307 same reporter/drug/event, different patient
itching tongue face lips,  mild swollen tongue and lips,  neck pain, hoarse voice, cough,  pale.  Progressively worse in order listed over 10 minutes.  Chewable benadryl 12.5 mg x 4 given.  Pt reported improved symptoms within 10 minutes and was asymptomatic at 30 minutes.
The patient is a bone marrow transplant patient. She was seen in the ED on 6/14/23, and reported she was away a few weeks ago when she contracted COVID (diagnosed two weeks ago). Her symptoms have been since worsening, and on that day she reported feeling really lethargic and tired. She additionally reported cough, diarrhea, nausea, and shortness of breath with exertion. Her husband noted the patient had a five-day Remdesivir infusion done at an outside clinic; this was completed three days ago. Ultimately, she was admitted 6/14/23 - 6/20/23. During her admission, she was started on 2L O2 with CT showing peripheral groundglass opacities consistent with COVID-19 pneumonia. Repeat COVID testing by PCR on 6/16 remained positive, and she was started on a second course of remdesivir on that day. During admission, she had increasing O2 needs, with O2 up to 15 L via high flow nasal cannula. Due to her increasing O2 needs and severe immunocompromise status, the patient was transferred to a Clinic - local Hospital. Of note, she has received the primary COVID-19 vaccine series and three boosters.
TIA/STROKE - OVERNIGHT HOSPITAL STAY AND OBSERVATION.  CT, MRI, EKG, ANGIOGRAM.  TROUBLE WALKING, LEFT HAND NOT WORKING CORRECTLY, LOW GRADE HEADACHE, CONFUSION, LETHERGY.
Very sore at injection site.  Diagnosed with shingles on arm, extremely painful arm. As of this date, arm still very sore and seems lumpy!
pediatric patients (children) were given the adult dose of Havrix.; pediatric patients (children) were given the adult dose of Havrix.; This case was reported by a physician via call center representative and described the occurrence of overdose in a patient who received HAV (Havrix adult) for prophylaxis.   On an unknown date, the patient received Havrix adult. On an unknown date, unknown after receiving Havrix adult, the patient experienced overdose and adult product administered to child. On an unknown date, the outcome of the overdose and adult product administered to child were unknown.  Additional details were provided as follows: The age at vaccination was not reported. The patient was given an adult dose of Havrix, which led to overdose and adult product administered to child. The pediatrician´s office was still trying to identify the patient. The patient identifiers were not available at the moment. The reporter consented to follow up. This case was one of 9 linked reports which were reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021120523:same reporter US-GLAXOSMITHKLINE-US2021120516:same reporter US-GLAXOSMITHKLINE-US2021120521:same reporter US-GLAXOSMITHKLINE-US2021120525:same reporter US-GLAXOSMITHKLINE-US2021120526:same reporter US-GLAXOSMITHKLINE-US2021120528:same reporter US-GLAXOSMITHKLINE-US2021AMR121314:same reporter US-GLAXOSMITHKLINE-US2021120519:same reporter
To my dad too, later after the vaccine/Suspected vaccination failure; To my dad too (shingles); This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a male patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: To my dad too, later after the vaccine/Suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: To my dad too (shingles)). The outcome of the vaccination failure was unknown and the outcome of the shingles was not reported.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.     It was unknown if the company considered the vaccination failure and shingles to be related to Shingles vaccine.   Additional Information: GSK receipt date: 10-MAR-2023 The case was received from the patient's son/daughter via interactive digital media. The patient got shingles too later after the Shingles vaccine. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting. The follow-up could not be possible as no contact details were available.
1st dose 01st August 2022, 2nd dose 19th August 2022; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 68-year-old male patient who received Herpes zoster (Shingrix) (batch number KJ937, expiry date 11th June 2023) for prophylaxis.   Concomitant products included RECOMBINANT VARICELLA ZOSTER VIRUS SURFACE GLYCOPROTEIN E (SHINGRIX).   On 19th August 2022, the patient received the 2nd dose of Shingrix. On 19th August 2022, unknown after receiving Shingrix, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown.   Additional Information: GSK Receipt Date: 19-Aug-2022 Reporter's Comments: The pharmacy manager reports administered the Shingrix 1st dose to a patient on 1st August 2022 and a 2nd dose on the reporting day. Additional Supportive Information: The patient received 2nd dose early than the recommended time interval, which led to shortening of vaccination schedule. The reporter did not consent to follow up.
Expired dose of Havrix administered; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 4-year-old male patient who received HAV (Havrix) (batch number 7HJ74, expiry date 21st August 2022) for prophylaxis.   On 22nd August 2022, the patient received Havrix. On 22nd August 2022, unknown after receiving Havrix, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.   Additional Information: GSK receipt date: 23-Aug-2022 Reporter's comment: The medical assistant reported that a patient was administered a dose Havrix after expiration date. The reporter consented to follow-up. Additional supportive information: The patient received an expired dose of Havrix, which led to expired vaccine used.
Patient reported to pharmacy she got the Pfizer vaccine on 12/10/2021 around 6:30 pm. Then she experienced pain, and swelling in armpit/neck lymph nodes. Pain and swelling still present on Monday 12/13/2021. Patient took Tylenol 500mg on 12/12/2021. Patient prescribed prednisone 10mg on 12/10/2021 but has not started the medication. Patient asked when she should start the prednisone after the Pfizer vaccine due to the adverse reaction. I advised her to follow-up with her provider that prescribed prednisone.
Right arm swelling very bad right after shot, next day woke up to get ready to work I started to get light headed, dizzy, sweating, felt like I was going to pass out. My husband then called 911. They took me to Hospital ,I stayed there for a couple hours then released. They told me to stay home and the next day I felt fine. I did a televisit  with my Nephrologist (Kidney doctor) the following week.
This spontaneous report as received from a nurse refers to a 15 year old patient of unknown gender. Medical history and concurrent conditions were not reported. On 05-MAR-2015, the patient was vaccinated with an improperly stored GARDASIL dose 3, lot # K005881, expiration date 14-JAN-2017 (dose and route were not reported). No adverse event reported. No co-suspect and concomitant therapies were reported. This is one of several reports from the same source. Additional information is not expected. All follow up requested to complete the case were received.
Fever for 5 days (often seemed to fluctuate ~99F, but up to 102.6F), followed by heavy congestion and sleep disruption for 1-2 nights. One small mucus vomit on day 1 Sat 7/23/22. Decent spirits during the day but reduced appetite (still ate though) and just running warm. After fever disappeared, he got miserable with the heavy congestion for couple days, then slowly got better by ~ Tues 8/2/22.
I had visual problems - seeing lightning bolts in both eyes. I was directed to my eye doctor who said this is a sign of a detached retina; I had visual problems - seeing lightning bolts in both eyes. I was directed to my eye doctor who said this is a sign of a detached retina; visual disturbances; This is a spontaneous report from a contactable consumer (patient). A 54-years-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Lot number: EP7533), via an unspecified route of administration in Arm left on 01Apr2021 at 02:30 PM as DOSE 1, SINGLE for COVID-19 immunization. Patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, lot number: EW0172), via an unspecified route of administration in Arm Right on 22Apr2021 at 02:30 PM (at the age of 54 years old) as DOSE 2, SINGLE for COVID-19 immunization. Medical history included High BP, migraine and known allergies to shellfish. Prior to vaccination, the patient was diagnosed with COVID-19. Concomitant medications included verapamil; magnesium; lisinopril; riboflavin; aluminium hydroxide, magnesium hydroxide (AMERACID) all were taken for an unspecified indication, start and stop date were not reported and all received within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. Device Date: 12Jul2021. After first dose on 02Apr2021 at 12:00 PM, patient had visual problems and was seeing lightning bolts in both eyes. Patient was directed to the eye doctor who found it to be a sign of a detached retina. Patient had to go through an exam and scan, but there was nothing wrong with the eyes. Patient symptoms went away within a week of the vaccine. The same exact symptoms happened after the second vaccine on 22Apr2021, with the second eye doctor appointment on 26Apr2021. Patient had to repeat an exam and scan with Eye doctor and he still couldn't find anything wrong. Patient's symptoms went away within a week after the second vaccine. These visual disturbances caused patient not to trust while driving. Patient's eye doctor said it seemed very suspicious that this happened right after patient received the vaccines. No treatment was received for the events. Events recovered on an unspecified date.  Follow-up attempts are completed. No further information is expected.; Sender's Comments: Based on the information in the case report and a plausible temporal relationship,  a possible causal relationship between the event retinal detachment and suspect drug BNT162B2 cannot be excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
Pain and tingling down arm from the injection site almost immediately. By that night the muscle was extremely sore and painful to the touch. By 48 hours there was heat, swelling and rash extending downward and outward from the injection site. Pain and severe itching continued for a week and a half.
Headache, Myalgia, Fever, fatique and chills Narrative: Called in sick for 2 days after symptoms resolved
If i got the first dose but it's been six weeks, do i have to start over with the first dose again?; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (If i got the first dose but it's been six weeks, do i have to start over with the first dose again?) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (If i got the first dose but it's been six weeks, do i have to start over with the first dose again?). At the time of the report, PRODUCT DOSE OMISSION ISSUE (If i got the first dose but it's been six weeks, do i have to start over with the first dose again?) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Throat tightening around 2:30 pm on day of injection and again around 9 am the day after. Both relieved after taking allergy medicine
A spontaneous report was received from a nurse concerning a White, 82-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced the event, after the vaccines lost temperature they were administered. The patient's medical history was not provided. No relevant concomitant medications were reported. On 11 Jan 2021, a refrigerator in a vaccine clinic lost power and rose up to room temperature overnight. At approximately 9 p.m., the vaccines inside the refrigerator reached room temperature. On 12 Jan 2021, after the vaccine lost temperature, the patient received their first of two planned doses of mRNA-1273 (Lot number: 027L20A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection.  No treatment information was provided.  Action taken with the second dose of mRNA-1273 in response to the event was not reported.  The event, after the vaccines lost temperature they were administered, was considered resolved on 12 Jan 2021.  .; Reporter's Comments: This case concerns a 82-year-old female patient who received their first of two planned doses of mRNA-1273 (Lot: 027L20A), reporting Out of specification product use.
Fever, nausea, headache, sore glands, fatigue  -slept, took aspirin- symptoms slightly better at 12:30pm 08/06/2022 but still some nausea , slight headache and fatigue.
Sinus headache; Runny nose; Sneezing; Cough; Dizziness; Extreme exaustion/Fatigue; Headache; This spontaneous case was reported by a consumer and describes the occurrence of SINUS HEADACHE (Sinus headache), RHINORRHOEA (Runny nose), SNEEZING (Sneezing), COUGH (Cough) and DIZZINESS (Dizziness) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19.    Concurrent medical conditions included Allergy to antibiotic (Bactrim).   On 01-Nov-2021 at 3:00 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Apr-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) at an unspecified dose. On 06-May-2022 at 3:00 PM, the patient experienced SINUS HEADACHE (Sinus headache), RHINORRHOEA (Runny nose), SNEEZING (Sneezing), COUGH (Cough), DIZZINESS (Dizziness), FATIGUE (Extreme exaustion/Fatigue) and HEADACHE (Headache). At the time of the report, SINUS HEADACHE (Sinus headache), RHINORRHOEA (Runny nose), SNEEZING (Sneezing), COUGH (Cough), DIZZINESS (Dizziness), FATIGUE (Extreme exaustion/Fatigue) and HEADACHE (Headache) was resolving.            No concomitant medication information provided.  Patient received no other medicines or products within two weeks of starting COVID-19 treatment. Device date was reported as 10-May-2022.  No treatment medication information provided.
Pt had Pneumovax at 0940. Never had one before. Pt called at 1640 c/o red, warm to touch, swollen arm. Exam revealed 11x13cm swollen area, warmth, non-tender, given Dexamethasone and took Benadryl through evening upon rev, decreased swelling. Still with erythema. Placed on antibiotics, cont. Benadryl.
Tinnitus.  Increases when pressing neck muscles near carotid artery or when extending jaw.
Extreme joint pain lasting; Chest painful with every breath; Could not sleep even; This is a spontaneous report from a non-contactable consumer, the patient. A 60-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the right arm on 11Mar2021 at 13:30 (at the age of 60-years-old), as a single dose for COVID-19 immunisation. Medical history included lung cancer and diabetes. The patient did not have allergies to medications, food, or other products. Concomitant medications included chemoradiation, metformin (MANUFACTURER UNKNOWN), rosuvastatin (MANUFACTURER UNKNOWN) and omeprazole (MANUFACTURER UNKNOWN); all taken for unknown indication from an unknown date. The patient had not received any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 11Mar2021 at 15:00, the patient experienced extreme joint pain which lasted for 15 hours. The patient also experienced chest pain with every breath and was not able to sleep with Tylenol PM, had to sit up in the chair for five hours, could not stand pain lying down and hence took 3 more Tylenol regular strength 4 hours after first dose. The chest pain then moved to neck area lasted rest of the day with Tylenol helped. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of joint pain, chest pain, sleep difficult and included treatment with TYLENOL. The clinical outcomes of the events joint pain, sleep difficult and chest pain was resolved in Mar2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Headache, mild nausea and fatigue. Since evening of vaccine - 10/28/08.
Chills and shaking started night of injection. next day slight headache and neck pain. vomiting several times over 15 hours. tired, slept 2 -3 hours several times throughout the day. Not able to function the entire day. I called Advise Nurse and was told to drink ginger tea, rest and drink fluids.
R arm swelling, painful for 24 hours. Dec range of motion. Sensitive to touch and felt burning sensation.
The next morning, passed out, vomiting, heart palpitations, nausea, shortness of breath